363 related articles for article (PubMed ID: 28619014)
21. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
[TBL] [Abstract][Full Text] [Related]
22. The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.
Zhang C; Wang L; Xiong C; Zhao R; Liang H; Luo X
J Orthop Surg Res; 2021 Dec; 16(1):738. PubMed ID: 34963495
[TBL] [Abstract][Full Text] [Related]
23. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer.
Kohli M; Kaushal V; Spencer HJ; Mehta P
Urology; 2003 Apr; 61(4):765-9. PubMed ID: 12670562
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor and basic fibroblast growth factor in patients with squamous cell oesophageal cancer.
Wallner G; Ciechański A; Dabrowski A; Kozłowski M; Roliński J; Laudański J; Cwik G
Folia Histochem Cytobiol; 2001; 39 Suppl 2():122-3. PubMed ID: 11820569
[TBL] [Abstract][Full Text] [Related]
25. Quantification of angiogenesis stimulators in children with solid malignancies.
Pavlakovic H; Von Schütz V; Rössler J; Koscielniak E; Havers W; Schweigerer L
Int J Cancer; 2001 Jun; 92(5):756-60. PubMed ID: 11340583
[TBL] [Abstract][Full Text] [Related]
26. Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma.
Wu H; Zhang J; Dai R; Xu J; Feng H
J Orthop Surg Res; 2019 Sep; 14(1):296. PubMed ID: 31484533
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma.
Graeven U; Andre N; Achilles E; Zornig C; Schmiegel W
J Cancer Res Clin Oncol; 1999 Oct; 125(10):577-81. PubMed ID: 10473871
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
Rossi B; Schinzari G; Maccauro G; Scaramuzzo L; Signorelli D; Rosa MA; Fabbriciani C; Carlo B
BMC Musculoskelet Disord; 2010 Feb; 11():34. PubMed ID: 20158913
[TBL] [Abstract][Full Text] [Related]
29. Serum angiogenic activity: diagnostic relevance in renal cell carcinoma.
Beecken WD; Bentas W; Glienke W; Linneweber J; Jonas D; Binder J; Kramer W
Eur Urol; 2002 Oct; 42(4):364-9. PubMed ID: 12361902
[TBL] [Abstract][Full Text] [Related]
30. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
31. Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma.
Lin F; Zheng SE; Shen Z; Tang LN; Chen P; Sun YJ; Zhao H; Yao Y
Med Oncol; 2011 Jun; 28(2):649-53. PubMed ID: 20349215
[TBL] [Abstract][Full Text] [Related]
32. High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma.
Hu F; Shang XF; Wang W; Jiang W; Fang C; Tan D; Zhou HC
Int J Exp Pathol; 2016 Feb; 97(1):86-92. PubMed ID: 27028305
[TBL] [Abstract][Full Text] [Related]
33. High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma.
Liu Y; Zhang F; Zhang Z; Wang D; Cui B; Zeng F; Huang L; Zhang Q; Sun Q
Pathol Res Pract; 2017 Aug; 213(8):895-899. PubMed ID: 28647210
[TBL] [Abstract][Full Text] [Related]
34. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma.
Dobrzycka B; Mackowiak-Matejczyk B; Kinalski M; Terlikowski SJ
Gynecol Oncol; 2013 Mar; 128(3):454-60. PubMed ID: 23206584
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in children with brain tumors.
Sobol-Milejska G; Mizia-Malarz A; Musiol K; Chudek J; Bożentowicz-Wikarek M; Wos H; Mandera M
Adv Clin Exp Med; 2017 Jul; 26(4):571-575. PubMed ID: 28691414
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review.
Qu JT; Wang M; He HL; Tang Y; Ye XJ
J Cancer Res Clin Oncol; 2012 May; 138(5):819-25. PubMed ID: 22274866
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.
Liu W; Zhao X; Zhang YJ; Fang GW; Xue Y
J Int Med Res; 2018 Mar; 46(3):975-983. PubMed ID: 29115164
[TBL] [Abstract][Full Text] [Related]
39. Angiogenic protein expression in advanced epithelial ovarian cancer.
Barton DP; Cai A; Wendt K; Young M; Gamero A; De Cesare S
Clin Cancer Res; 1997 Sep; 3(9):1579-86. PubMed ID: 9815846
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma.
Fujiwara T; Uotani K; Yoshida A; Morita T; Nezu Y; Kobayashi E; Yoshida A; Uehara T; Omori T; Sugiu K; Komatsubara T; Takeda K; Kunisada T; Kawamura M; Kawai A; Ochiya T; Ozaki T
Oncotarget; 2017 May; 8(20):33375-33392. PubMed ID: 28380419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
